Murine double minute 2: p53-independent roads lead to genome instability or death

Trends in Biochemical Sciences

Volumn 34, Issue 6, 2009, Pages 279-286

  Bouska, Alyssa ^a   Eischen, Christine M ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NUTLIN 3; PACLITAXEL; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; DNA REPAIR; DNA REPLICATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; CELL DEATH; CHROMOSOMAL INSTABILITY; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION REGULATION; GENOME; MICE; MODELS, BIOLOGICAL; MODELS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 66949142488     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2009.02.006     Document Type: Review

References (80)

1. Fakharzadeh S.S., et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10 (1991) 1565-1569
2. Bond G.L., et al. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5 (2005) 3-8
3. Zhang Z., et al. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets 5 (2005) 9-20
4. Aylon Y., et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 20 (2006) 2687-2700
5. Rayburn E., et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5 (2005) 27-41
6. Cordon-Cardo C., et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54 (1994) 794-799
7. Lu M.L., et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res. 8 (2002) 171-179
8. Alt J.R., et al. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 22 (2003) 1442-1450
9. Eischen C.M., et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13 (1999) 2658-2669
10. McDonnell T.J., et al. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 188 (1999) 322-328
11. Jones S.N., et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15608-15612
12. Harris L.C. MDM2 splice variants and their therapeutic implications. Curr. Cancer Drug Targets 5 (2005) 21-26
13. Carroll P.E., et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18 (1999) 1935-1944
14. Lundgren K., et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11 (1997) 714-725
15. Wang P., et al. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27 (2008) 1590-1598
16. Wang P., et al. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 25 (2006) 3708-3718
17. Schneider B.L., et al. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 25 (2004) 2033-2044
18. Zhou R., et al. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Res. 65 (2005) 1839-1848
19. Sdek P., et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20 (2005) 699-708
20. Martin K., et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375 (1995) 691-694
21. Xiao Z.X., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375 (1995) 694-698
22. Mundle S.D., et al. Evolving intricacies and implications of E2F1 regulation. FASEB J. 17 (2003) 569-574
23. Wunderlich M., et al. Mdm2 inhibition of p53 induces E2F1 transactivation via p21. Oncogene 21 (2002) 4414-4421
24. Sdek P., et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J. Biol. Chem. 279 (2004) 53317-53322
25. Uchida C., et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24 (2005) 160-169
26. Dubs-Poterszman M.C., et al. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11 (1995) 2445-2449
27. Reinke V., et al. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 10 (1999) 147-154
28. Folberg-Blum A., et al. Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila. Oncogene 21 (2002) 2413-2417
29. Boyd M.T., et al. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J. Biol. Chem. 275 (2000) 31883-31890
30. Brady M., et al. Regulation of p53 and MDM2 activity by MTBP. Mol. Cell. Biol. 25 (2005) 545-553
31. Iwakuma T., et al. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 27 (2008) 1813-1820
32. Jin Y., et al. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22 (2003) 6365-6377
33. WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006
34. Kawai H., et al. DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278 (2003) 45946-45953
35. de Graaf P., et al. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 278 (2003) 38315-38324
36. Pan Y., et al. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23 (2003) 5113-5121
37. Jin Y., et al. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol. Cell. Biol. 28 (2008) 1218-1229
38. McCulloch S.D., et al. The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res. 18 (2008) 148-161
39. Pursell Z.F., et al. DNA polymerase epsilon: a polymerase of unusual size (and complexity). Prog. Nucleic Acid Res. Mol. Biol. 82 (2008) 101-145
40. Vlatkovic N., et al. MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase ε. Nucleic Acids Res. 28 (2000) 3581-3586
41. Asahara H., et al. Stimulation of human DNA polymerase ε by MDM2. Nucleic Acids Res. 31 (2003) 2451-2459
42. Jang H., et al. Genetic and epigenetic interactions between folate and aging in carcinogenesis. J. Nutr. 135 (2005) 2967S-2971S
43. Ulrich C.M. Folate and cancer prevention - where to next? Counterpoint. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 2226-2230
44. Maguire M., et al. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res. 68 (2008) 3232-3242
45. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 9 (2003) 2593-2613
46. Acilan C., et al. A tale of too many centrosomes. Cell 134 (2008) 572-575
47. Matijasevic Z., et al. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice. Mol. Cell. Biol. 28 (2008) 1265-1273
48. Alt J.R., et al. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J. Biol. Chem. 280 (2005) 18771-18781
49. Bouska A., et al. Mdm2 promotes genetic instability and transformation independent of p53. Mol. Cell. Biol. 28 (2008) 4862-4874
50. Zhang Y., et al. The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res. 16 (2006) 45-54
51. de Toledo S.M., et al. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene 19 (2000) 6185-6193
52. Stevens C., et al. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst.) 3 (2004) 1071-1079
53. Sapountzi V., et al. Cellular functions of TIP60. Int. J. Biochem. Cell Biol. 38 (2006) 1496-1509
54. Legube G., et al. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 21 (2002) 1704-1712
55. Zhivotovsky B., et al. Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol. 5 (2004) 752-762
56. Zhang Z., et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11636-11641
57. Loughran O., et al. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol. 20 (2000) 2186-2197
58. Dilla T., et al. The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation. Oncogene 21 (2002) 2376-2386
59. Ambrosini G., et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26 (2007) 3473-3481
60. Kitagawa M., et al. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27 (2008) 5303-5314
61. Pietsch E.C., et al. The p53 family and programmed cell death. Oncogene 27 (2008) 6507-6521
62. Irwin M., et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407 (2000) 645-648
63. Calabro V., et al. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem. 277 (2002) 2674-2681
64. Kadakia M., et al. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 20 (2001) 321-330
65. Dobbelstein M., et al. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18 (1999) 2101-2106
66. Zeng X., et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19 (1999) 3257-3266
67. Ongkeko W.M., et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 9 (1999) 829-832
68. Watson I.R., et al. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J. Biol. Chem. 281 (2006) 34096-34103
69. Kim J.W., et al. TIP60 represses transcriptional activity of p73β via an MDM2-bridged ternary complex. J. Biol. Chem. 283 (2008) 20077-20086
70. Jeong M.H., et al. p19ras interacts with and activates p73 by involving the MDM2 protein. J. Biol. Chem. 281 (2006) 8707-8715
71. Lau L.M., et al. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27 (2008) 997-1003
72. Hu M.C., et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004) 225-237
73. Yang J.Y., et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 10 (2008) 138-148
74. Lu T., et al. Cytokine overexpression and constitutive NFκB in cancer. Cell Cycle 3 (2004) 1114-1117
75. Gu L., et al. MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99 (2002) 3367-3375
76. Cheney M.D., et al. MDM2 displays differential activities dependent upon the activation status of NFκB. Cancer Biol. Ther. 7 (2008) 38-44
77. Froment P., et al. Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 7 (2008) 3098-3103
78. Tao Y., et al. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 4 (2007) 591-602
79. Girnita L., et al. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8247-8252
80. Vazquez A., et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7 (2008) 979-987